Glucose 5% Intravenous Infusion BP
*Company:
Baxter Holding B.V.Status:
No Recent UpdateLegal Category:
Product subject to medical prescription which may not be renewed (A)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 02 June 2025
File name
Glucose 5% UK.IE.MT Sept 24-pil-clean.pdf
Reasons for updating
- Change to section 6 - manufacturer
- Change to section 6 - date of revision
Updated on 04 June 2024
File name
ie_spc_Glucose 5_PA2299-003-001_June 2023.pdf
Reasons for updating
- Change to section 6.5 - Nature and contents of container
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 03 August 2023
File name
Glucose 5% PIL CB-30-02-784_06MAY22_P03.pdf
Reasons for updating
- New PIL for new product
Updated on 24 January 2023
File name
ie-spc-glu5-clean.pdf
Reasons for updating
- Document format updated
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 28 April 2022
File name
ie-spc-glu5-clean.pdf
Reasons for updating
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 29 March 2021
File name
ie_spc_Gloucose 5_PA2299-003-001_March 2019.pdf
Reasons for updating
- Change to section 6.5 - Nature and contents of container
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 13 September 2019
File name
ie-spc-2019-03-g5-PA2299003001-c.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 7 - Marketing authorisation holder
- Change to section 8 - Marketing authorisation number(s)
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 28 November 2016
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 28 November 2016
Reasons for updating
- Change to section 6.5 - Nature and contents of container
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 28 November 2016
Reasons for updating
- Change to section 6.5 - Nature and contents of container
- Change to section 10 - Date of revision of the text
Free text change information supplied by the pharmaceutical company
Updated on 01 September 2016
Reasons for updating
- New SPC for medicines.ie
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 01 September 2016
Reasons for updating
- New SPC for medicines.ie
Free text change information supplied by the pharmaceutical company
Baxter Holding B.V.
Address:
Kobaltweg 49, 3542CE Utrecht, NetherlandsMedical Information E-mail:
medinfo_uki@baxter.comTelephone:
+44 (0)1635 206 345Medical Information Facsimile:
+44 (0)1635 206071Medical Information Direct Line:
+44 (0)1635 206345